Treatment for the endocrine resistant breast cancer: Current options and future perspectives

被引：40
作者：
Liu, Chun-Yu [1 ,3 ]
Wu, Chia-Yun [1 ,3 ]
Petrossian, Karineh [4 ]
Huang, Tzu-Ting [1 ]
Tseng, Ling-Ming [2 ,3 ]
Chen, Shiuan [4 ]
机构：
[1] Dept Oncol, Div Med Oncol, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan
[3] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[4] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, 1500 East Duarte Rd, Duarte, CA 91010 USA
来源：
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 2017年 / 172卷
关键词：
Endocrine resistance; Hormone receptor; Estrogen receptor; Breast cancer; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; NONSTEROIDAL AROMATASE INHIBITORS; EVEROLIMUS PLUS EXEMESTANE; PENTOSE-PHOSPHATE PATHWAY; RANDOMIZED PHASE-II; HORMONE-RECEPTOR; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; TAMOXIFEN RESISTANCE;
D O I：
10.1016/j.jsbmb.2017.07.001
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Endocrine resistance remains a challenge and an unmet need for managing hormone receptor-positive breast cancer. The mechanisms of endocrine resistance are multifaceted and are likely to evolve over time following various single or combination therapies. The purpose of this review article is to provide general understanding of molecular basis of endocrine resistance of breast cancer and to offer comprehensive review on current treatment options and potential new treatment strategies for endocrine resistant breast cancers. Last but not the least, we discuss current challenges and future directions for management of endocrine resistant breast cancers.
引用
收藏
页码：166 / 175
页数：10
相关论文
共 144 条
[1]   Role of epigenetic modifications in luminal breast cancer [J].
Abdel-Hafiz, Hany A. ;
Horwitz, Kathryn B. .
EPIGENOMICS, 2015, 7 (05) :847-862
[2]   Estrogen receptor mutations and their role in breast cancer progression [J].
Alluri, Prasanna G. ;
Speers, Corey ;
Chinnaiyan, Arul M. .
BREAST CANCER RESEARCH, 2014, 16 (06)
[3]  
Anbalagan M., 2015, MOL CELL ENDOCRINOL
[4]   Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database [J].
Anderson, WF ;
Chatterjee, N ;
Ershler, WB ;
Brawley, OW .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 (01) :27-36
[5]  
[Anonymous], SAN ANT BREAST CANC
[6]   Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance [J].
Arpino, Grazia ;
Wiechmann, Lisa ;
Osborne, C. Kent ;
Schiff, Rachel .
ENDOCRINE REVIEWS, 2008, 29 (02) :217-233
[7]   Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].
Bachelot, Thomas ;
Bourgier, Celine ;
Cropet, Claire ;
Ray-Coquard, Isabelle ;
Ferrero, Jean-Marc ;
Freyer, Gilles ;
Abadie-Lacourtoisie, Sophie ;
Eymard, Jean-Christophe ;
Debled, Marc ;
Spaeth, Dominique ;
Legouffe, Eric ;
Allouache, Djelila ;
El Kouri, Claude ;
Pujade-Lauraine, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724
[8]  
Baselga J., 2014, SAN ANT BREAST CANC
[9]   Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].
Baselga, Jose ;
Campone, Mario ;
Piccart, Martine ;
Burris, Howard A., III ;
Rugo, Hope S. ;
Sahmoud, Tarek ;
Noguchi, Shinzaburo ;
Gnant, Michael ;
Pritchard, Kathleen I. ;
Lebrun, Fabienne ;
Beck, J. Thaddeus ;
Ito, Yoshinori ;
Yardley, Denise ;
Deleu, Ines ;
Perez, Alejandra ;
Bachelot, Thomas ;
Vittori, Luc ;
Xu, Zhiying ;
Mukhopadhyay, Pabak ;
Lebwohl, David ;
Hortobagyi, Gabriel N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529
[10]   INSULIN-LIKE GROWTH FACTORS, INSULIN, AND GROWTH HORMONE SIGNALING IN BREAST CANCER: IMPLICATIONS FOR TARGETED THERAPY [J].
Beckwith, Heather ;
Yee, Douglas .
ENDOCRINE PRACTICE, 2014, 20 (11) :1214-1221
12345678910